Recent epidemiological evidence relevant to the clinical management of the menopause

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 2-15

  Shapiro, S ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Bias; Breast cancer; Coronary heart disease; Epidemiology; Hormone therapy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

ADULT; AGED; BREAST CANCER; CANCER DIAGNOSIS; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; FEMALE; HAZARD RATIO; HEALTH SERVICE; HEALTH SERVICES RESEARCH; HORMONAL THERAPY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSE; MILLION WOMEN STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE; VENOUS THROMBOEMBOLISM; WOMEN HEALTH INITIATIVE;

EID: 34548850645     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701606754     Document Type: Conference Paper

References (55)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative. JAMA 2002;288:321-33
2. Million Women Study Collaborators. Breast cancer and hormone therapy in the Million Women Study. Lancet 2003;362:419-27
3. Kelly JP, Kaufman DK, Rosenberg L, Kelley K, Cooper SG, Mitchell AM. Use of postmenopausal hormone therapy since the Women's Health Initiative Findings. Pharmacoepidemiol Drug Safety 2005;14:837-42
4. Schneider HPG, Naftolin F, eds. Climacteric Medicine - where do we go? London: Taylor and Francis, 2004
5. Naftolin F, Schneider HPG, Sturdee DW. The Writing Group for the IMS Executive Committee. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004;7:8-11
6. Naftolin F, Schneider HPG, Sturdee DW. The Writing Group for the IMS Executive Committee. Guidelines for hormone treatment of women in the menopausal transition and beyond. Position Statement by the Executive Committee of the International Menopause Society. Revised October 15, 2004. Climacteric 2004;7:333-7
7. Shapiro S. Commentary: Is meta-analysis a valid approach to the evaluation of small effects in epidemiological studies? J Clin Epidemiol 1997;50:223-9
8. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and risk of coronary heart disease. N Engl Med J 2003;349:523-34
9. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-12
10. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative Clinical Trial. Am J Epidemiol 2005;162:1-11
11. Petitti DB, Freedman DA. How far can epidemiologists get with statistical adjustment? Am J Epidemiol 2005;162:415-18
12. Prentice RL, Langer R, Anderson G, Barad D. Prentice et al respond to 'How far can epidemiologists get with statistical adjustment?' Am J Epidemiol 2005;162:419-20
13. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003;290:1729-38
14. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004
15. Cushman M, Kuller LH, Rodabough RJ, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
16. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54
17. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 2004;291:2947-58
18. Stefanick ML, Anderson GL, Margolis K, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
19. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breastcancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-18
20. Chilvers CED, Knobb RC, Armstrong SJ, Woods KL, Logan RFA. Post menopausal hormone replacement therapy and myocardial infarction - a case control study of women in the East Midlands, UK. Eur Heart J 2003;24:2197-205
21. de Vries CS, Bromley SE, Farmer RDT. Myocardial infarction risk and hormone replacement: differences between products. Maturitas 2006;53:343-50
22. Newcomer LM, Newcomb PA, Potter JD, et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 2003;14:225-33
23. Olsson HL, Ingvar C, Baldstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-92
24. Li CL, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63
25. Tjommeland A, Christensen J, Thomsen B, et al. Hormone replacement therapy in relation to breast carcinoma incidence ratios. A prospective Danish study. Cancer 2004;100:2328-37
26. Chen WY, Hankinson SE, Schnitt SJ. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500
27. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regiments of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721-7
28. Stahlberg C, Peersen AT, Anderrsen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004;91:644-50
29. Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-54
30. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish Cohort Study. Br J Cancer 2005;92:1293-7
31. Lee S, Kolonel L, Wilkens L, et al. Postmenopausal hormone therapy and breast cancer risk: The Multiethnic Cohort. Int J Cancer 2006;118:1285-91
32. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 2006;17:695-703
33. Lyytinen H, Pukkala E, Ylikorkola O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60
34. Rosenberg LU, Magnusson C, Lindstrom E, et al. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological sub-types of breast cancer: a case-control study. Breast Cancer Res 2006l;8:R11 Epub Feb 17
35. Suzuki R, Rylznder-Rudqvist WY, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer 2006;119:1683-9
36. Tamimi RM, Hankinson SE, Chen WY, et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-9
37. Dinger J, Heinemann LAJ, Mohner S, Thai DM, Assmann A. Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Women's Health 2006;6:13
38. Lacey JV, Brinton LA, Lubin J, et al. Endometrial carcinoma risks among menopausal estrogen and progestin users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1724-31
39. Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006;164:775-86
40. Lacey JV, Mink P, Lubin J, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41
41. Glus E, Kjaer SK, Birthe LT, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004;164:2253-9
42. Lacey JV, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst 2006;98:1397-405
43. Moorman PG, Schildkraut JM, Calingaert B, et al. Menopausal hormones and risk of ovarian cancer. Obstet Gynecol 2005;193:76-82
44. Folsom A, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004;15:100-4
45. Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric 2006;9:416-20
46. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
47. Meade TW, Hsia J, Johnson KC, et al. HRT and cardiovascular disease. J Epidemiol Biostat 1999;4:165-90
48. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;5:302-10
49. Garbe E, Suissa S. Issues to be debated on the Women's Health Study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13
50. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer. Lancet 1996;347:1713-27
51. Beral V, Banks E, Reeves G, et al. The effect of hormone replacement therapy on breast and other cancers. In Critchley H, Gebbie A, Beral V, eds. Menopause and Hormone Replacement. London: Royal College of Obstetrics and Gynaecology Press, 2004
52. Shapiro S. The Million Women Study. Potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7
53. van Leeuwen FE, Rookus MA. Breast cancer and hormone-replacement therapy: the Million Women Study (letter). Lancet 2002;362:1330-1
54. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini review. Hum Reprod 2005;20:2052-60
55. Cogliano V, Grosse Y, Baan R, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552-3